Bristol-Myers Squibb (NYSE:BMY) traded up 1.1%

Shares of Bristol-Myers Squibb (NYSE:BMY – Get Free Report ) were up 1.1% during mid-day trading on Friday. The company traded as high as $40.81 and last traded at $40.69. About 3,166,923 shares were traded during trading, down 79% from the average daily volume of 15,409,910 shares. Shares previously closed at $40.25.

Analysts on Wall Street are forecasting an increase

BMY has been the subject of several recent analyst reports. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com upgraded Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. Wells Fargo & Company upped their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research report on Thursday, April 18th. BMO Capital Markets reduced their price objective on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th . Finally, Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $60.00, according to MarketBeat.

Get the latest stock analysis on BMY

Bristol-Myers Squibb trading rose 2.1%

The company has a market cap of $83.29 billion, a price-to-earnings ratio of -13.25, a price-to-earnings-growth ratio of 13.63 and a beta of 0.45. The company’s 50-day moving average price is $46.69 and its 200-day moving average price is $49.29. The company has a debt-to-equity ratio of 2.99, a quick ratio of 0.99, and a current ratio of 1.11.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The company’s quarterly revenue was up 4.7% year over year. During the same period last year, the company posted earnings of $2.05 per share. research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Institutional inputs and outputs

Institutional investors and hedge funds have recently bought and sold shares of the company. Milestone Investment Advisors LLC bought a new stake in Bristol-Myers Squibb during the 3rd quarter valued at about $27,000. ESL Trust Services LLC bought a new stake in shares of Bristol-Myers Squibb in the first quarter valued at about $27,000. Northwest Financial Advisors purchased a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at $27,000. Accordant Advisory Group Inc bought a new position in Bristol-Myers Squibb in the first quarter worth $31,000. Finally, Pacific Capital Wealth Advisors Inc. purchased a new position in Bristol-Myers Squibb in the 4th quarter valued at $34,000. Institutional investors and hedge funds own 76.41% of the company’s shares.

Bristol-Myers Squibb Company Profile

(Get a free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Read more

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.